Cargando…

Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells

SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) is an intractable subset of breast cancer without an efficient therapeutic strategy due to the lack of tractable targets, such as the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Activation and/or amplifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	You, Kyu Sic, Yi, Yong Weon, Cho, Jeonghee, Seong, Yeon-Sun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000364/ https://www.ncbi.nlm.nih.gov/pubmed/33801977 http://dx.doi.org/10.3390/cancers13061205

Ejemplares similares

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
por: You, Kyu Sic, et al.
Publicado: (2021)

Inhibition of IκB Kinase Is a Potential Therapeutic Strategy to Circumvent Resistance to Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer Cells
por: Yi, Yong Weon, et al.
Publicado: (2022)

Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6
por: YI, YONG WEON, et al.
Publicado: (2015)

Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells
por: Yi, Yong Weon, et al.
Publicado: (2013)

An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer
por: van der Noord, Vera E., et al.
Publicado: (2019)

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
por: Lim, Bora, et al.
Publicado: (2021)

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
por: El Guerrab, Abderrahim, et al.
Publicado: (2020)

Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib
por: Song, Xiang, et al.
Publicado: (2020)

HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer
por: Han, Shuyan, et al.
Publicado: (2023)

Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?
por: Yi, Yong Weon, et al.
Publicado: (2021)

Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems
por: Nagaria, Teddy S., et al.
Publicado: (2017)

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
por: Koh, Siang-Boon, et al.
Publicado: (2021)

Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer
por: Liu, Zhaoyun, et al.
Publicado: (2017)

Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer
por: Zhang, Zhizhu, et al.
Publicado: (2022)

Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway
por: Zhang, Ying, et al.
Publicado: (2022)

HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel
por: Lyu, Hui, et al.
Publicado: (2023)

Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer
por: Tian, Xueli, et al.
Publicado: (2022)

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib
por: WANG, XINZHAO, et al.
Publicado: (2015)

Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer
por: Matossian, Margarite D., et al.
Publicado: (2021)

Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer
por: Choi, Cheolwon, et al.
Publicado: (2016)

Differential gene expression and AKT targeting in triple negative breast cancer
por: Lin, Feng-Mao, et al.
Publicado: (2019)

Role of AMPK and Akt in triple negative breast cancer lung colonization
por: Johnson, Jeremy, et al.
Publicado: (2021)

Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma
por: Ewald, Florian, et al.
Publicado: (2015)

Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer
por: Kim, Min Woo, et al.
Publicado: (2019)

NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest
por: Diluvio, Giulia, et al.
Publicado: (2018)

Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
por: Jokinen, Elina, et al.
Publicado: (2012)

Anti-Proliferative Effect of Cytohesin Inhibition in Gefitinib-Resistant Lung Cancer Cells
por: Bill, Anke, et al.
Publicado: (2012)

PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer
por: Wang, Xueyan, et al.
Publicado: (2022)

Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway
por: Ramakrishnan, Vijay, et al.
Publicado: (2012)

Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8(+) T-cells infiltration in triple-negative breast cancer
por: Kalimutho, Murugan, et al.
Publicado: (2019)

Isochromanoindolenines suppress triple-negative breast cancer cell proliferation partially via inhibiting Akt activation
por: Jiang, Xiaoyan, et al.
Publicado: (2021)

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
por: Sorokin, Alexey V., et al.
Publicado: (2022)

Anti-cancer Activity of Centipeda minima Extract in Triple Negative Breast Cancer via Inhibition of AKT, NF-κB, and STAT3 Signaling Pathways
por: Lee, Magnolia Muk-Lan, et al.
Publicado: (2020)

Dual inhibition of the MEK/ERK and PI3K/AKT pathways prevents pulmonary GVHD suppressing perivenulitis and bronchiolitis
por: Muranushi, Hiroyuki, et al.
Publicado: (2022)

Tumor-Targeted Erythrocyte Membrane Nanoparticles for Theranostics of Triple-Negative Breast Cancer
por: Choi, Moon Jung, et al.
Publicado: (2023)

Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells
por: Wu, Kai, et al.
Publicado: (2013)

Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway
por: Shao, Guoli, et al.
Publicado: (2021)

Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer
por: Jouali, Farah, et al.
Publicado: (2018)

Sevoflurane Modulates AKT Isoforms in Triple Negative Breast Cancer Cells. An Experimental Study
por: Tiron, Crina E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_903ktnstctva860lso69386561